What is Natera?
Natera is a global leader in cell-free DNA (cfDNA) testing, with a specialized focus on oncology, women's health, and organ health. By integrating personalized genetic testing into the standard of care, the company enables earlier and more targeted clinical interventions. Its market position is defined by a robust diagnostic pipeline that addresses critical unmet needs in patient monitoring and disease management, effectively bridging the gap between complex genomic data and actionable clinical insights.
The company's growth has been supported by a diverse syndicate of institutional backers, including early-stage venture firms and multi-stage investment managers. This financial backing has facilitated the scaling of its laboratory infrastructure and the expansion of its commercial reach, allowing Natera to maintain its competitive edge in the rapidly evolving molecular diagnostics sector.
How much funding has Natera raised?
Natera has raised a total of $1B across 12 funding rounds:
Grant
$2M
Series D
$20M
Series E
$54.6M
Series F
$55.5M
Stock Offering
$180M
Stock Offering
$90M
Stock Offering
$100M
Stock Offering
$200M
Debt
$287.5M
Grant (2011): $2M featuring National Institutes of Health
Series D (2012): $20M backed by Claremont Creek Ventures, Lightspeed Venture Partners, and Steamboat Ventures
Series E (2013): $54.6M with participation from Claremont Creek Ventures, Founders Fund, OrbiMed, Harmony Group Capital, Lightspeed Venture Partners, and Steamboat Ventures
Series F (2015): $55.5M led by Jennison Associates, HealthCor Partners, Sofinnova Ventures, Steamboat Ventures, RA Capital Management, Franklin Templeton Investments, Capital Research and Management, and OrbiMed
Stock Issuance/Offering (2015): $180M, investors not publicly disclosed
Stock Issuance/Offering (2018): $90M, investors not publicly disclosed
Stock Issuance/Offering (2019): $100M, investors not publicly disclosed
Stock Issuance/Offering (2019): $200M, investors not publicly disclosed
Debt (2020): $287.5M, investors not publicly disclosed
Key Investors in Natera
Claremont Creek Ventures
A seed and early-stage venture firm focusing on IT-driven opportunities with deep domain expertise in digital healthcare and online businesses.
Steamboat Ventures
A venture firm founded in 2000 that focuses on helping early to growth-stage companies in the technology, media, and consumer sectors become market leaders.
Lightspeed Venture Partners
A global multistage venture capital firm that partners with founders across sectors including enterprise software, consumer, and fintech from seed through IPO.
What's next for Natera?
Looking ahead, Natera is positioned to leverage its recent capital influx to accelerate the adoption of its cfDNA solutions across broader clinical applications. The strategic focus remains on enhancing the precision of its diagnostic tools and expanding its footprint in the oncology and organ health markets. As the company continues to mature, the emphasis will likely shift toward scaling operational efficiencies and deepening its integration within global healthcare systems, ensuring that its genetic testing capabilities become a foundational element of personalized medicine.
See full Natera company page
